Herman Cueto Sells 1,595 Shares of Azenta, Inc. (NASDAQ:AZTA) Stock

Azenta, Inc. (NASDAQ:AZTA) CFO Herman Cueto sold 1,595 shares of the firm’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $43.68, for a total value of $69,669.60. Following the completion of the transaction, the chief financial officer now directly owns 24,604 shares in the company, valued at approximately $1,074,702.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Azenta Price Performance

AZTA stock opened at $43.64 on Wednesday. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -16.04 and a beta of 1.47. Azenta, Inc. has a 1-year low of $43.15 and a 1-year high of $69.16. The business has a 50 day simple moving average of $47.88 and a two-hundred day simple moving average of $51.78.

Azenta (NASDAQ:AZTA) last issued its earnings results on Tuesday, August 6th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.09. The firm had revenue of $173.00 million during the quarter, compared to analyst estimates of $166.14 million. Azenta had a negative net margin of 23.66% and a positive return on equity of 0.89%. Azenta’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.13 earnings per share. Sell-side analysts anticipate that Azenta, Inc. will post 0.33 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $69.00 price objective on shares of Azenta in a research note on Wednesday, August 7th. Evercore ISI dropped their price target on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $66.40.

Institutional Investors Weigh In On Azenta

A number of hedge funds have recently made changes to their positions in the company. Hantz Financial Services Inc. bought a new stake in Azenta in the 2nd quarter worth approximately $30,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Azenta during the first quarter valued at $38,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Azenta during the first quarter valued at $49,000. Lazard Asset Management LLC purchased a new position in shares of Azenta in the 1st quarter worth $130,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Azenta by 24.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after buying an additional 471 shares during the last quarter. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.